April 21, 2014 4:35 AM ET

Biotechnology

Company Overview of NKT Therapeutics, Inc.

Company Overview

NKT Therapeutics, Inc., a biotechnology company, engages in developing therapeutics based on immune cells called natural killer T cells (NKT). It focuses to develop a pipeline of NKT based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2008 and is based in Waltham, Massachusetts.

1000 Winter Street

Suite 3900

Waltham, MA 02451

United States

Founded in 2008

Phone:

781-684-0290

Fax:

781-684-0291

Key Executives for NKT Therapeutics, Inc.

Chief Executive Officer
Co-founder and Member of Scientific Advisory Board
Vice President of Finance
Chief Medical Officer
Age: 57
Chief Scientifc Officer
Compensation as of Fiscal Year 2013.

NKT Therapeutics, Inc. Key Developments

NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease

NKT Therapeutics, Inc. announced preclinical study results supporting the potential of its lead therapeutic candidate, NKTT120, as an innovative approach to the treatment of sickle cell disease. Preclinical studies of NKTT120, a humanized monoclonal antibody, showed its ability to generate a safe, rapid, specific and complete depletion of invariant Natural Killer T cells (iNKT cells) 24 hours post dosing, thus offering a means to reduce the chronic inflammation associated with sickle cell disease pathology. NKT Therapeutics plans to initiate a clinical trial of NKTT120 in patients with stable sickle cell disease in the first quarter of 2013. NKTT120 is a humanized monoclonal antibody that results in a safe, rapid, specific and complete depletion of iNKT cells. The presented research showed that a specific and complete depletion of iNKT cells was observed at the earliest post dosing measurement at 24 hours, and was maintained throughout the 85 day study. Investigators observed no adverse events, infections, or cytokine release. T cell-dependent antibody response to KLH antigen was not affected by NKTT120 treatment. Chronic inflammation is associated with the pathology of sickle cell disease, and studies by NKT Therapeutics and others have found an increased ratio of activated iNKT cells in the peripheral blood of patients with sickle cell disease. These findings suggest that iNKT cell reduction and/or depletion would be effective in reducing the damaging inflammation associated with sickle cell disease.

Similar Private Companies By Industry

Company Name Region
Oncotide Pharmaceuticals Inc United States
TheraKine Inc. United States
InCytu, Inc. United States
Egenix, Inc. United States
Tyrogenex, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NKT Therapeutics, Inc., please visit www.nktrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.